Advances in antibody-drug conjugate-based combination therapy strategies for non-small cell lung cancer
- Published on 07/28/2026
- Reading time: 1 min.
Yunqi Mi , Shan Wang , Yuhao Wang , Shiqi Ding , Jinxiang Wu & Jing Yu *
Cancer Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China
CONTACT Jing Yu mailto:yujing026@ccmu.edu.cn Cancer Center, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong an Road, Xi Cheng District, Beijing 100050, China
Abstract
Introduction Non-small cell lung cancer (NSCLC) continues to be one of the leading causes of cancer death worldwide. Although targeted therapies and immune checkpoint inhibitors have meaningfully improved outcomes for some patients, many still lack targetable mutations or quickly develop resistance. Antibody-drug conjugates (ADCs), which combine tumor-specific antibodies with potent cytotoxic payloads, have become an increasingly promising option.
Areas covered...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Oncology
Receive our newsletter to stay up to date with the latest news in Oncology
